流式细胞仪检测恶性淋巴瘤患者外周血T细胞亚群的临床研究

doi:10.11904/j.issn.1002-3070.2017.05.008

摘要/Abstract

摘要：

目的探讨流式细胞仪检测恶性淋巴瘤患者外周血T细胞亚群的效果及其与临床病理、肿瘤类型的关系。方法选取我院于2014年8月—2016年9月收治的98例恶性淋巴瘤患者为研究组,同期选取98例健康体检者为对照组。应用流式细胞仪检测两组外周血T细胞亚群(CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺)并进行比较。结果研究组CD3⁺、CD4⁺/CD8⁺水平分别为(55.63±11.25),(1.32±0.62),显著低于对照组的(68.96±12.63),(1.59±0.59),差异具有统计学意义(P＜0.05);研究组CD4⁺、CD8⁺水平(33.67±8.14),(26.02±4.67)与对照组的(34.12±8.33),(25.67±4.53)相比差异无统计学意义(P＞0.05)。霍奇金淋巴瘤、非霍奇金淋巴瘤患者CD3⁺、CD4⁺/CD8⁺水平分别为(54.63±11.36),(1.22±0.65)和(55.52±12.02),(1.34±0.71),显著低于对照组的(68.96±12.63),(1.59±0.59),差异具有统计学意义(P＜0.05);霍奇金淋巴瘤、非霍奇金淋巴瘤患者CD4⁺、CD8⁺水平分别为(33.78±8.23),(25.74±4.88)和(33.62±8.74),(26.32±4.85)与对照组的(34.12±8.33),(25.67±4.53)相比,差异无统计学意义(P＞0.05)。Ⅲ~Ⅳ期恶性淋巴瘤患者CD3⁺、CD4⁺、CD4⁺/CD8⁺水平分别为(52.66±12.47),(28.25±6.32),(1.30±0.62)明显低于对照组的(68.96±12.63),(34.12±8.33),(1.59±0.59),差异具有统计学意义(P＜0.05);Ⅰ~Ⅱ期恶性淋巴瘤患者CD3⁺水平为(58.63±11.85),显著低于对照组的(68.96±12.63),而CD8⁺水平为(29.63±3.57),显著高于对照组的(25.67±4.53),差异具有统计学意义(P＜0.05)。结论流式细胞仪检测外周血T细胞亚群可以作为诊断恶性淋巴瘤患者的病情、分期以及免疫状态的重要手段,具有较高的应用价值。

关键词: 流式细胞仪, 恶性淋巴瘤, 外周血T细胞亚群

Abstract:

Objective The aim of this study was to investigate the effect of flow cytometry on peripheral blood T cell subsets in patients with malignant lymphoma and its relationship with clinicopathological and tumor types.Methods Ninety-eight patients with malignant lymphoma treated in our hospital from August 2014 to September 2016 were selected as the study group.Ninety-eight healthy subjects were selected as the control group.The peripheral blood T cell subsets(CD3⁺,CD4⁺,CD8⁺,CD4⁺/CD8⁺)were detected in patients and healthy controls by flow cytometry.Results The levels of CD3⁺ and CD4⁺/CD8⁺ in the study group were(55.63±11.25)and(1.32±0.62),respectively,which were significantly lower than those(68.96±12.63)and(1.59±0.59)of the control group(P＜0.05).The levels of CD4⁺ and CD8⁺ were(33.67±8.14)and(26.02±4.67),respectively in the study group,were no difference from the control group(34.12±8.33)and(25.67±4.53)(P＞0.05).The levels of CD3⁺ and CD4⁺/CD8⁺ in patients with Hodgkin's lymphoma were(54.63±11.36),(1.22±0.65),respectively,and(55.52±12.02),(1.34±0.71)for non-hodgkin lymphoma.They were significantly decreoseg in the control group(68.96±12.63 for CD3⁺ and 1.59±0.59 for CD4⁺/CD8⁺)(P＜0.05).The level of CD4⁺ and CD8⁺were no difference amoupst Hodgkin's lymphoma(33.78±8.23 for CD4⁺ and 25.74±4.88 for CD8⁺),non-Hodgkin's lymphoma(25.74±4.88 for CD4⁺ and 33.62±8.74 for CD8⁺)and control group(34.12±8.33 for CD4⁺ and 25.67±4.53 for CD8⁺)(P＞0.05).The levels of CD3⁺,CD4⁺ and CD4⁺/CD8⁺ in patients with Ⅲ ~Ⅳ stage malignant lymphoma were(52.66±12.47),(28.25±6.32)and(1.30±0.62),respectively,which were significantly lower than those(68.96±12.63),(34.12±8.33)and(1.59±0.59)in the control group(P＜0.05).The level of CD3⁺ in patients with phase I-II malignant lymphoma(58.63±11.85)was significantly lower than that in the control group(68.96±12.63)(P＜0.05).The level of CD8⁺ in patients with phase I-II malignant lymphoma(29.63±3.57)was significantly higher than that in the control group(25.67±4.53)(P＜0.05).Conclusion The detection of peripheral blood T cell subsets by flow cytometry can be used as an important methods to diagnose the disease,staging and immune status of patients with malignant lymphoma,which has high application value.

Key words: Flow cytometry, Malignant lymphoma, Peripheral blood T cell subsets

中图分类号:

R733

王景胜, 刘正君, 陈楠, 李丹, 高会广. 流式细胞仪检测恶性淋巴瘤患者外周血T细胞亚群的临床研究[J]. 实用肿瘤学杂志, 2017, 31(5): 431-435.

WANG Jingsheng, LIU Zhengjun, CHENG Nan, LI Dan, GAO Huiguang. Clinical study of peripheral blood T cell subsets in patients with malignant lymphoma by flow cytometry[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 431-435.

参考文献

1 何春燕,徐琼,曹丽芳,等.非霍奇金淋巴瘤患者的病理类型及分布特点[J].浙江临床医学,2016,18(11):2112-2113.
2 易思华,张晓薇,赵丽,等.多参数流式细胞术在非霍奇金淋巴瘤诊断中的应用及价值[J].国际检验医学杂志,2013,34(22):2982-2983.
3 吴宜嘉.流式细胞仪在淋巴瘤患者外周血T细胞亚群诊断中的应用研究[J].海南医学院学报,2010,16(2):1660-1662.
4 Waldman M,Crew RJ,Valeri A,et al.Adult minimal-change disease:clinical characteristics,treatment,and outcomes[J].J Am Soc Nephrol,2007,2(11):445-453.
5 邹煦,常炳庆,黄新春,等.恶性淋巴瘤患者外周血T淋巴细胞亚群变化的讨论[J].癌症进展,2012,10(4):396-398.
6 Sahali D,Pawlak A,Le Gouvello S,et al.Transcriptional and post-transcriptionalalterations of Ikappa Baloha in active minimal change nephritic syndrome[J].J Am Soc Nephrol,2001,12(8):1648-1658.
7 Morita R,Schmitt N,Bentebibel SE,et al.Human blood CXCR5(+)CD4(+)T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion[J].Immunity,2011,34:108-121.
8 袁顺宗,苏航.利用嵌合抗原受体的T细胞(CAR-T)治疗复发和难治B细胞淋巴瘤/白血病的转化医学研究[J].中国实验血液学杂志,2014,22(4):1137-1141.
9 邹煦,常炳庆,黄新春,等.恶性淋巴瘤患者外周血T淋巴细胞亚群变化的讨论[J].癌症进展,2012,10(4):396-398,404.
10 Veldhoen M,Hocking RJ,Atkins CJ,et al.TGF beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17 producing T cells[J].Immunity,2006,24(2):179-189.
11 Feintzeig ID,Dittmer JE,Cybulsky AV,et al.Antibody,antigen,and glomerular capillary wall change interactions:influence of antigen location on in situ immune complexformation[J].Kidney Int,2006,29(3):649-657.
12 Zhou W,Andrews PA,Wang Y,et al.Evidence for increased synthesis of complement C4 in the renal epithelium of rats with passive heymann nephritis[J].J Am Soc Nephrol,2007,8(2):214-222.
13 Lagrue G,Xheneumont S,Branellec A,et al.A vascular permeability factor elaborated from lymphocytes I Demonstration in patients with nephritic syndrome[J].Biomedicine,2015,23(1):37-40.
14 Cho MH,Lee HS,Choe BH,et al.Interleukin-8 and tumor necrosis factor-alpha are increased in minimal change disease but do not alter albumin permeability[J].Am J Nephrol,2003,23(4):260-266.
15 马军,朱军,石远凯,等.T细胞淋巴瘤研究新进展:2014年国际T细胞淋巴瘤临床治疗大会报道[J].白血病·淋巴瘤,2014,23(11):641-645,653.
16 Selllier-Leclerc AI,Duval A,Riceron S,et al.A humanized mouse model of idiopathicnephritic syndrome suggests a pathogenic role for immature cells[J].J Am Soc Nephrol,2007,18(11):2732-2739.
17 杨德芬.外周血T细胞亚群检测在恶性肿瘤中的应用及临床意义[J].海南医学院学报,2013,19(10):1390-1392.
18 Ettinger R,Sims GP,Fairhurst AM,et al.IL-21 induces differentiation of human nave and memory B cells into antibody-secreting plasma cells[J].J Immunol,2005,175(12):7867-7879.
19 Bryant VL,Ma CS,Avery DT,et al.Cytokine mediated regulation of human B cell differentiation into Ig-secreting cells:predominant role of IL-21 produced by CXCR5+ T follicular helper cells[J].J Immunol,2007,192(12):8180-8190.
20 武晓博.难治性淋巴瘤患者外周血T淋巴细胞亚群与自然杀伤细胞表达水平的检测及其临床意义[D].太原:山西医科大学,2011:5-7.
21 乔文斌.弥漫大B细胞淋巴瘤患者外周血T淋巴细胞亚群与NK细胞检测的临床意义[D].乌鲁木齐:新疆医科大学,2011:9-12.

[1]	刘玉, 王子安. 原发性胃肠道恶性淋巴瘤术后生存期的影响因素及TNM分期对远期生存的预测价值分析[J]. 实用肿瘤学杂志, 2018, 32(4): 315-319.
[2]	郭莉综述,张清媛审校. Toll样受体4在恶性淋巴瘤中的作用[J]. 实用肿瘤学杂志, 2014, 28(5): 456-459.
[3]	陈炬莹, 陈晓耕. 乳腺癌细胞系中肿瘤干细胞相关亚群的初步研究[J]. 实用肿瘤学杂志, 2012, 26(5): 432-437.
[4]	李俊;丁祖玖;洪素珍;程洁;朱扬;翟倩. 激光扫描显微镜对恶性淋巴瘤细胞学诊断初步研究[J]. 实用肿瘤学杂志, 2001, 15(04): 241-242.
[5]	郭晓临;王立娥;李莉;袁缓. 白细胞介素-8在胃癌组织中的表达及意义[J]. 实用肿瘤学杂志, 2001, 15(04): 255-256.
[6]	张涛;张剑军;赵岩;赵宜良;吴晓飞. 54例原发性胃恶性淋巴瘤诊治的探讨[J]. 实用肿瘤学杂志, 2001, 15(03): 196-198.
[7]	宋福山;王雅杰;王立波;冯立艳. 儿童恶性淋巴瘤72例临床分析[J]. 实用肿瘤学杂志, 2001, 15(01): 48-49.
[8]	张烨. 扁桃体恶性淋巴瘤49例临床分析[J]. 实用肿瘤学杂志, 2000, 14(04): 280-281.
[9]	陈昂;李守业;庞兆刚. 睾丸原发性恶性淋巴瘤的治疗与预后(附16例报告)[J]. 实用肿瘤学杂志, 2000, 14(04): 302-303.
[10]	胡云;刘颖;郑建华. 子宫内膜腺癌中DNA含量和端粒酶活性的临床分析[J]. 实用肿瘤学杂志, 2000, 14(03): 201-203.
[11]	乔文波;赵彦辉;王春波;阚玉成;王瑞芝. 原发眶内恶性淋巴瘤的临床治疗分析[J]. 实用肿瘤学杂志, 2000, 14(03): 205-206.
[12]	孙艳丽;陈武;宋秀云. 原发性胃肠道恶性淋巴瘤 (附25例报告)[J]. 实用肿瘤学杂志, 2000, 14(02): 102-104.